Healthcare is in its GLP-1 era. Following Novo Nordisk’s blockbuster success with Ozempic and Wegovy, many drugmakers are focused on developing new iterations of weight loss drugs that could come with fewer side effects and drive down costs.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
